COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Vaginal Estrogen for Asymptomatic Microscopic Hematuria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03033160
Recruitment Status : Recruiting
First Posted : January 26, 2017
Last Update Posted : October 12, 2017
Beth Israel Deaconess Medical Center
Mount Auburn Hospital
Information provided by (Responsible Party):
Lekha S. Hota, Boston Urogynecology Associates

Brief Summary:
The specific aim of this protocol is to determine whether vaginal estrogen is an effective treatment for asymptomatic microscopic hematuria in postmenopausal women. The investigators hypothesize that women who use vaginal estrogen for three months will be more likely to have resolution of their asymptomatic microscopic hematuria compared with women who do not use vaginal estrogen.

Condition or disease Intervention/treatment Phase
Asymptomatic Microscopic Hematuria Drug: Estradiol Ring Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Masking Description: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of Vaginal Estrogen to Treat Asymptomatic Microscopic Hematuria
Study Start Date : December 2016
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : December 30, 2020

Arm Intervention/treatment
Experimental: Estradiol Ring
Estradiol Ring per vagina every 3 months
Drug: Estradiol Ring
Other Name: Estring

No Intervention: Observation

Primary Outcome Measures :
  1. Comparison of microscopic hematuria (RBC's) at 12 weeks compared to baseline measurement [ Time Frame: 12 weeks ]
    Investigators will compare red blood cell count results obtained during the initial urinalysis to the 12 week urinalysis to measure any change in red blood cell count (if any).

Secondary Outcome Measures :
  1. Comparison of Microscopic Hematuria (RBC's) at 24 weeks compared to baseline. [ Time Frame: 24 weeks ]
    Investigators will cimpare red blood cell count results obtained during the initial Urinalysis to the 24 week urinalysis to measure any change in red blood cell count (if any).

  2. To Assess Quality of Life [ Time Frame: 12 weeks ]
    Measurement of quality of life change from baseline, utilizing subject self administered questionnaires, Urogenital Distress Inventory Short Form (UDI-6) and the Incontinence Impact Questionnaire-short Form (IIQ-7)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal, defined by amenorrhea for at least one year or a bilateral oophorectomy at least one year prior, and have three or more red blood cells per high powered field visible in a properly collected urine specimen without evidence of infection. In addition, women must have a negative cystoscopy and computed tomography urogram (or magnetic resonance urography if history of renal insufficiency or contrast allergy) within the past three years.

Exclusion Criteria:

  • Current or past thromboembolic disorder or cerebrovascular accident
  • Intolerance to previous estrogen replacement therapy or hormone replacement therapy
  • Estrogen dependent neoplasm within the past five years (unless supporting documentation from patient's oncologist is obtained)
  • Estrogen replacement therapy or hormone replacement therapy within the past three months or selective estrogen receptor modulators within eight weeks of enrollment
  • Urinary tract infection
  • Urinary calculi
  • Urinary tract malignancy
  • Vaginal bleeding of unknown origin
  • Urethral caruncle
  • History of recurrent urinary tract infections in the last one year
  • Stage two or greater pelvic organ prolapse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03033160

Layout table for location contacts
Contact: Kathleen Rogers 614-354-5452

Layout table for location information
United States, Massachusetts
Mount Auburn Hospital Recruiting
Cambridge, Massachusetts, United States, 02138
Contact: Kathleen Rogers    617-354-5452   
Sponsors and Collaborators
Boston Urogynecology Associates
Beth Israel Deaconess Medical Center
Mount Auburn Hospital
Layout table for investigator information
Principal Investigator: Lekha Hota, MD Practitioner
Layout table for additonal information
Responsible Party: Lekha S. Hota, Clinical Instructor Division of Urogynecology and Female Pelvic Medicine and Reconstructive Surgery, Boston Urogynecology Associates Identifier: NCT03033160    
Other Study ID Numbers: 052-2015
First Posted: January 26, 2017    Key Record Dates
Last Update Posted: October 12, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Lekha S. Hota, Boston Urogynecology Associates:
Additional relevant MeSH terms:
Layout table for MeSH terms
Urination Disorders
Urologic Diseases
Pathologic Processes
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs